Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome: A Multicenter, Randomized Study
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Efficacy of symbiotics in patients with irritable bowel syndrome (IBS) remains unknown. METHODS: Patients were randomized to a prebiotic (n=135), or a symbiotic formulation containing Lactobacillus paracasei B21060 (Flortec, n=132). Primary efficacy was the responder rate for pain and global relief of symptoms in the overall population and in patients with predominant diarrhea (n=47). Post hoc time-trend analyses for changes within each treatment were carried out. RESULTS: Patients with absent/mild pain amounted to 54.7% in the symbiotic group and to 57.4% in the prebiotic group at treatment week 4, and to 53.9% and 53.4% at the end of treatment. Patients with amelioration of well-being were, respectively, 60.7% versus 61.7% at treatment week 4, and 63.3% versus 60.9% at the end of treatment. Within each treatment group, patients with absent/mild pain increased in the Flortec and the prebiotic group, but time trend analyses were significant only for Flortec (P=0.019). In IBS-predominant diarrhea, Flortec significantly reduced bowel movements, pain, and IBS scores. CONCLUSIONS: To improve pain and well-being, Flortec is encouraging in patients with diarrhea predominant IBS. To establish its efficacy for the majority of IBS patients, Flortec has to be compared with an inert placebo in future work.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With regard to synbiotics, there are some studies but their design is not sufficiently robust to draw any firm conclusions251–255 although the concept of combining a prebiotic and probiotic is theoretically attractive.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [251]
Citations
Cites
Dietary modulation of the human colonic microbiota: updating the concept of prebiotics
Gibson, G. R., Probert, H. M., Loo, J. V., Rastall, R. A., & Roberfroid, M. B. (2004) · Nutrition Research Reviews · doi:10.1079/nrr200479 · Cited by 2,536 · cited 1×
“As shown in human studies, supplementation with fructose-oligosaccharides leads to considerable changes in the composition of the fecal flora.(16,17) This would mean that in our study the placebo was not inert but acted as a prebiotic.”
ResultFunctional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Postinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Activation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833
Malinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699
Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis
D'Souza, A. L., Rajkumar, C., Cooke, J., & Bulpitt, C. J. (2002) · BMJ · doi:10.1136/bmj.324.7350.1361 · Cited by 664 · cited 1×
“Lactobacilli are considered to be safe for healthy and immunosuppressed individuals.(20,21) Twenty-five subjects in the symbiotic group and 30 in the placebo had symptoms worsened during the study, but only 5 and 4 subjects, respectively, withdrew from the study because of adverse effects.”
BackgroundSafety of Probiotics That Contain Lactobacilli or Bifidobacteria
Borriello, S. P., Hammes, W. P., Holzapfel, W., Marteau, P., Schrezenmeir, J., Vaara, M., & Valtonen, V. (2003) · Clinical Infectious Diseases · doi:10.1086/368080 · Cited by 551 · cited 1×
“Lactobacilli are considered to be safe for healthy and immunosuppressed individuals.(20,21) Twenty-five subjects in the symbiotic group and 30 in the placebo had symptoms worsened during the study, but only 5 and 4 subjects, respectively, withdrew from the study because of adverse effects.”
BackgroundDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Onset and Disappearance of Gastrointestinal Symptoms and Functional Gastrointestinal Disorders
Talley, N. J., Weaver, A. L., Zinsmeister, A. R., & Melton, L. J. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116483 · Cited by 475 · cited 1×
“As shown in human studies, supplementation with fructose-oligosaccharides leads to considerable changes in the composition of the fecal flora.(16,17) This would mean that in our study the placebo was not inert but acted as a prebiotic.”
ResultMeta‐analysis: the effect of probiotic administration on antibiotic‐associated diarrhoea
Cremonini, F., Di Caro, S., Nista, E. C., Bartolozzi, F., Capelli, G., Gasbarrini, G., & Gasbarrini, A. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01318.x · Cited by 384
Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel
Langlands, S. J. (2004) · Gut · doi:10.1136/gut.2003.037580 · Cited by 359
Spiller, R. C. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00324-x · Cited by 356
Post-infectious irritable bowel syndrome
Thabane, M., & Marshall, J. K. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.3591 · Cited by 189
Design of treatment trials for functional gastrointestinal disorders
van Zanten, S. J. O. V., Talley, N. J., Bytzer, P., Klein, K. B., Whorwell, P. J., & Zinsmeister, A. R. (1999) · Gut · doi:10.1136/gut.45.2008.ii69 · Cited by 157
The putative role of inflammation in the irritable bowel syndrome
COLLINS, S. M., PICHE, T., & RAMPAL, P. (2001) · Gut · doi:10.1136/gut.49.6.743 · Cited by 154
Banaszkiewicz, A., & Szajewska, H. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.10.022 · Cited by 150
TSUCHIYA, J., BARRETO, R., OKURA, R., KAWAKITA, S., FESCE, E., & MAROTTA, F. (2004) · Chinese Journal of Digestive Diseases · doi:10.1111/j.1443-9573.2004.00176.x · Cited by 108
Recommendations for Probiotic Use
Floch, M. H., Madsen, K. K., Jenkins, D. J. A., Guandalini, S., Katz, J. A., Onderdonk, A., Walker, W. A., Fedorak, R. N., & Camilleri, M. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200603000-00022 · Cited by 88 · cited 1×
“Experts’ opinion has recently endorsed the use of probiotics in the treatment of certain gastrointestinal disorders, for example, adult and childhood infectious diarrhea, antibiotic-associated diarrhea, and pouchitis.(6) Literature data about the use of symbiotics in IBS is scant, with only 2 uncontrolled and 1 contro…”
BackgroundClinical trial guidelines for pharmacological treatment of irritable bowel syndrome
Corazziari, E., Bytzer, P., Delvaux, M., Holtmann, G., Malagelada, J. R., Morris, J., Muller‐Lissner, S., Spiller, R. C., Tack, J., & Whorwell, P. J. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01709.x · Cited by 80
Placebos: a review of the placebo response
THOMPSON, W. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)00971-0 · Cited by 69 · cited 1×
“A major problem with designing randomized trials for the treatment of IBS is the high and variable response in controls,(13,14) which reflects the tendency for IBS to remit spontaneously.(15) However, in our patients the effect on symptoms relief appeared within the first week after instituting therapy, rendering a sp…”
MethodEffects of symbiotic preparations on constipated irritable bowel syndrome symptoms.
Dughera, L., Elia, C., Navino, M., & Cisarò, F. (2007) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · Cited by 44
Whitehead, W. E., Corazziari, E., Prizont, R., Senior, J. R., Thompson, W. G., & van Zanten, S. J. O. V. (1999) · Gut · doi:10.1136/gut.45.2008.ii78 · Cited by 40
Colecchia, A., Vestito, A., Rocca, A. L., Pasqui, F., Nikiforaki, A., & Festi, D. (2006) · PubMed · Cited by 38
Germs, Gas and the Gut; the Evolving Role of the Enteric Flora in IBS
Quigley, E. M. M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00445.x · Cited by 34 · cited 1×
“Although it is accepted that IBS is probably not a single syndrome, and may well encapsulate several different pathophysiologies, it is now clear that at least a subset of these patients have differences in their gut microbiota.(1,2) The delineation of a postinfective variety of the syndrome that may occur in up to 30…”
Background
Cited by
Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645
Preidis, G. A., & Versalovic, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.072 · Cited by 485
Diagnosis and Treatment of Irritable Bowel Syndrome: A Review
Camilleri, M. (2021) · JAMA · doi:10.1001/jama.2020.22532 · Cited by 362
Metadata
- Authors
- Andriulli, A., Neri, M., Loguercio, C., Terreni, N., Merla, A., Cardarella, M. P., Federico, A., Chilovi, F., Milandri, G. L., De Bona, M., Cavenati, S., Gullini, S., Abbiati, R., Garbagna, N., Cerutti, R., & Grossi, E.
- Affiliations
- Casa Sollievo della Sofferenza (IT)
- University of Chieti-Pescara (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Ospedale Valduce (IT)
- Ospedale di Bolzano (IT)
- Ospedale “M. Bufalini” di Cesena (IT)
- Corresponding author
- Andriulli, Angelo
- Merla, Antonio
- Cavenati, Sergio
- ORCID
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2008-09
- Volume
- 42
- Issue
- Supplement 3
- Pages
- S218-S223
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2031153328
- Cited by
- 75
- References
- 25
- Citations by year
- 2025: 1 · 2024: 6 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 5 · 2014: 9 · 2013: 2 · 2012: 8
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, symbiotics, prebiotics, Lactobacillus paracasei, abdominal pain, well-being, defecation, probiotics
- MeSH terms
- Adult, Double-Blind Method, Drug Synergism, Female, Glutamine, Humans, Lactobacillus, Male, Middle Aged, Oligosaccharides, Treatment Outcome, Probiotics, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.